Journal Guide

The European Research Area has now become a reality. The prime objective of the EJECE is to fully document advances in European scientific and technical research in the fields of sustainable construction and environmental engineering. In particular regard to the latter, the environmental preservation of natural media (soils and rocks) and the mitigation of soil pollutions, natural and technological risks are now not only major societal challenges, but they are also the source of scientific and technical developments that could be extremely beneficial.Areas covered by the EJECE include rheology of geomaterials (cement, soils, rocks), natural media (muds, snow, ice, etc.) and granular materials, soil-fluid-structure interactions and their coupling with temperature, chemistry (degradation, etc.) and time (durability, ageing, etc.), computation and design of structures and engineering works. The new experimental facilities and measurement tools (metrology and sensors in laboratories and in the field, etc.) and the characterizing of displacement fields and of micro-meso-structures of materials (scanner, tomodensitometer, etc.) give rise to major innovations which concern thus primarily the EJECE . Finally the numerical methods (finite differences, finite elements, discrete elements, particulate methods, etc), which constitute obviously the bases of the modelling and of the computation of structures and engineering works, fall completely in the interest area of the Journal.Furthermore, as issues related to the environment are obviously of a pluridisciplinary nature, contributions based on probability, reliability studies or statistics, geology or geophysics, thermodynamics, physics of divided matter or chemistry of materials are welcome.The Journal has a wide audience that extends from public and private researchers to engineers in research departments or companies, and aspects linked to applications or to normalisation will also be published.

The European Journal of General Practice (EJGP) is the official journal of WONCA Europe, the European Society of General Practice/Family Medicine.

All published research articles in this journal have undergone rigorous peer review, based on initial editor screening and anonymous refereeing by independent expert referees. Disclaimer The British Phycological Society and Taylor & Francis makes every effort to ensure the accuracy of all the information (the 'Content') contained in its publications. However, the British Phycological Society and Taylor & Francis and its agents and licensors make no representations or warranties whatsoever as to the accuracy, completeness or suitability for any purpose of the Content and disclaim all such representations and warranties whether expressed or implied to the maximum extent permitted by law. Any views expressed in this publication are the views of the authors and are not the views of the Society and Taylor & Francis.

Special Issue Call For Papers! Evidence Based Practice: Using EBCAI Effectively Psychology Press is pleased to announce Evidence-Based Communication Assessment and Intervention - an international journal under the joint editorship of Dr. Ralf W. Schlosser, Professor, Department of Speech-Language Pathology and Audiology, Northeastern University, Boston, U.S.A., and Dr. Jeff Sigafoos, Professor, Victoria University of Wellington, New Zealand.Evidence-Based Communication Assessment and Intervention (EBCAI) brings together professionals from several disciplines to promote evidence-based practice (EBP) in serving individuals with communication impairments. We target speech-language pathologists, special educators, regular educators, applied behavior analysts, clinical psychologists, physical therapists, and occupational therapists who serve children or adults with communication impairments. We select and appraise the latest and highest quality studies and reviews related to assessment, intervention, diagnosis, and prognosis published across 60+ professional journals in speech-language pathology and related fields. We make these appraisals accessible through value-added structured abstracts that include expert commentary about the quality of the evidence as well as its practical implications. This affords the practitioner a one-stop reading experience to stay on top of research findings in order to facilitate evidence-based decision-making. Researchers and university professors will benefit from access to cutting-edge and clinically relevant studies.EBCAI also provides a forum for the dissemination of original research and discussion of methodologies and concepts that advance EBP as well as of experiential accounts of relevant stakeholders involved in the EBP process. Please consult the Information for Authors for the specific kinds of submissions EBCAI seeks to publish. Special IssuesIssues devoted to a single topic are regularly published in this journal; these are sent free to subscribers in that year, and are also available to purchase separately as books for non-subscribers. Click on the title below for more information and to order.Teaching Evidence-Based PracticeEditors: Ralf Schlosser and Jeff SigafoosVolume 3, Issue 4 (2009) ISBN 978-1-84872-730-4Related LinksBrowse books in Speech & Communication Disorders, and view forthcoming conferences in Language Disorders.Disclaimer Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in its publications. However, Taylor & Francis and its agents and licensors make no representations or warranties whatsoever as to the accuracy, completeness or suitability for any purpose of the Content and disclaim all such representations and warranties whether expressed or implied to the maximum extent permitted by law. Any views expressed in this publication are the views of the authors and are not the views of Taylor & Francis.

Experimental Heat Transfer provides a forum for experimentally based high quality research articles and communications in the general area of heat-mass transfer and the related fluid dynamics. In addition to the established multifaceted areas of thermal energy conversion and transport that are intimately connected to heat transfer related research, the journal also communicates contributions from new and emerging areas of research such as micro- and nanoscale science and technology, life sciences and biomedical engineering, manufacturing processes, materials science, and engineering. In all of these areas heat transfer plays an important role, in particular, in the form of innovative experiments and systems for direct measurements and analysis, as well as to verify or complement theoretical models. All contributions to the journal add to the knowledge base in heat transfer from the standpoint of fundamentals or applications. All papers are thoroughly peer refereed. Publication office: Taylor & Francis, Inc., 325 Chestnut Street, Suite 800, Philadelphia, PA 19106.

Aims & ScopeWelcome to Experimental Mathematics, a journal devoted to experimental aspects of mathematics research. It publishes original papers featuring formal results inspired by experimentation, conjectures suggested by experiments, and data supporting significant hypotheses. Experimental Mathematics, refereed in the traditional manner, is led by a first-rate editorial board. A high standard of exposition is maintained, in order to reach as many readers as possible.

Expert Opinion on Biological Therapy ranks #42 of 160 in the Biotechnology & Applied Microbiology category and #30 of 106 in the Medicine, Research & Experimental category in the 2009 ISI Journal Citation Reports.Expert Opinion on Biological Therapy (ISSN 1471-2598 [print], 1744-7682 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on all aspects of biological therapy, providing expert opinion on the scope for future development.The Editors welcome: * Reviews covering gene therapy and gene transfer technologies; therapeutic peptides and proteins; vaccines and antibodies; cell- and tissue-based therapies * Drug Evaluations reviewing the clinical data on a particular biological agent * Original research papers reporting the results of clinical investigations on biological agents and biotherapeutic-based studies with a strong link to clinical practiceThe audience consists of scientists and managers in the healthcare and biopharmaceutical industry and others closely involved in the development of biological therapy for the treatment of human disease.

Expert Opinion on Drug Delivery ranks #32 of 249 in the in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Drug Delivery (ISSN 1742-5247 [print], 1744-7593 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles covering all aspects of drug delivery research, from initial concept to potential therapeutic application and final relevance in clinical use. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.The Editors welcome: * Reviews covering delivery technologies, vehicles and devices; nanotechnology; novel formulations; the delivery of specific drug and therapeutic classes; gene/vaccine delivery strategies; modes of entry into the body and applications in certain diseases and disorders * Technology Evaluations reviewing a particular drug delivery technologyThe audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and others closely involved in the delivery of drugs and other therapeutic agents.

Expert Opinion on Drug Discovery ranks #176 of 249 in the in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Drug Discovery (ISSN 1746-0441 [print], 1746-045X [electronic]) is a peer-reviewed, international journal publishing review articles on novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.The Editors welcome: * Reviews covering chemoinformatics; bioinformatics; assay development; novel screening technologies; in vitro/in vivo models; structure-based drug design; systems biology * Drug Case Histories examining the steps involved in the preclinical and clinical development of a particular drug * Perspectives on topical issues with potential impact on the future of drug discoveryThe audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and other closely related professionals looking to enhance the success of their drug candidates through optimisation at the preclinical level.

Expert Opinion on Drug Metabolism & Toxicology ranks #66 of 249 in the Pharmacology & Pharmacy category and #112 of 286 in the Biochemistry and Molecular Biology category in the 2010 ISI Journal Citation Reports.Expert Opinion on Drug Metabolism & Toxicology (ISSN 1742-5255 [print], 1744-7607 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of ADME-Tox. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.The Editors welcome: * Reviews covering metabolic, pharmacokinetic and toxicological issues relating to specific drugs, drug classes or their use in specific populations; issues relating to enzymes involved in the metabolism, disposition and excretion of drugs; techniques involved in the study of drug metabolism and toxicology; novel technologies for obtaining ADME-Tox data * Drug Evaluations reviewing the clinical, toxicological and pharmacokinetic data on a particular drugThe audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and related professionals.

Expert Opinion on Drug Safety ranks #100 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development. * Reviews covering occurrence, management and prevention of drug-associated adverse events; risk-benefit analyses of individual drugs and drug classes; safety in 'at-risk' patient populations; comparative tolerability studies; pharmacovigilance and pharmacoepidemiological studies * Drug Safety Evaluations reviewing the safety data on a particular drug * Original Research papers reporting the results of post-marketing surveillance and other safety studies looking at specific drugs, populations and outcomes; methods for the detection and evaluation of drug-associated adverse eventsThe audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in monitoring drug safety.Read More: http://informahealthcare.com/page/Description?journalCode=eds.

Expert Opinion on Emerging Drugs ranks #69 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.Each review article is structured to include: * Concise background to the subject matter * Assessment of medical need for alternative or novel therapies * Assessment of the market and anticipated changes over time * Summary of current research goals * Outline of the scientific rationale for the approach(es) considered< * Analysis of the competitive environment * Discussion of potential development issues * The author’s expert opinion on the potential impact emerging therapies will have on the current management of specific diseasesThe audience consists of pharmaceutical and academic scientists, research planners, pharmaceutical product mangers, clinical opinion leaders and healthcare planners.

Expert Opinion on Investigational Drugs ranks #35 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. * Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies * Drug Evaluations reviewing the clinical and pharmacological data on a particular drug * Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trialsThe audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.

Expert Opinion on Orphan Drugs will be an international, peer-reviewed journal that covers all aspects of R&D on rare diseases and orphan drugs.